Article thumbnail

Broad-Spectrum Antiviral Therapeutics

By Todd H. Rider, Christina E. Zook, Tara L. Boettcher, Scott T. Wick, Jennifer S. Pancoast and Benjamin D. Zusman


Currently there are relatively few antiviral therapeutics, and most which do exist are highly pathogen-specific or have other disadvantages. We have developed a new broad-spectrum antiviral approach, dubbed Double-stranded RNA (dsRNA) Activated Caspase Oligomerizer (DRACO) that selectively induces apoptosis in cells containing viral dsRNA, rapidly killing infected cells without harming uninfected cells. We have created DRACOs and shown that they are nontoxic in 11 mammalian cell types and effective against 15 different viruses, including dengue flavivirus, Amapari and Tacaribe arenaviruses, Guama bunyavirus, and H1N1 influenza. We have also demonstrated that DRACOs can rescue mice challenged with H1N1 influenza. DRACOs have the potential to be effective therapeutics or prophylactics for numerous clinical and priority viruses, due to the broad-spectrum sensitivity of the dsRNA detection domain, the potent activity of the apoptosis induction domain, and the novel direct linkage between the two which viruses have never encountered

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2001). African swine fever virus IAP homologue inhibits caspase activation and promotes cell survival in mammalian cells.
  2. (2009). Anti-pathogen treatments.
  3. (2007). Apoptosome: a platform for the activation of initiator caspases.
  4. (2007). Athanasiadis A
  5. (2007). Caspase inhibitors: viral, cellular and chemical.
  6. (2007). Diverse functions of RNase L and implications in pathology.
  7. (1996). Double-stranded (ds) RNA binding and not dimerization correlates with the activation of the dsRNA-dependent protein kinase (PKR).
  8. (2006). Homotypic FADD interactions through a conserved RXDLL motif are required for death receptor-induced apoptosis.
  9. (2009). Human caspases: activation, specificity, and regulation.
  10. (2008). Interferon-inducible antiviral effectors.
  11. (2008). Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures.
  12. (2004). Knockdown by RNAiā€”proceed with caution.
  13. (2006). Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging.
  14. (2009). Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.
  15. (1998). NMR structure and mutagenesis of the FADD (Mort1) death-effector domain.
  16. (2010). Recognition of viral nucleic acids in innate immunity.
  17. (1999). Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1.
  18. (2007). Structure and function of the protein kinase R.
  19. (2006). Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins.
  20. (2001). Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo.
  21. (2007). TAT transduction: the molecular mechanism and therapeutic prospects.
  22. (2007). The human 29-59oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 29-59 instead of 39-59 phosphodiester bond formation.
  23. (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.
  24. (2005). Viral chemokinemodulatory proteins: tools and targets.
  25. (2008). Viral control of mitochondrial apoptosis.
  26. (2009). Viral inhibitors reveal overlapping themes in regulation of cell death and innate immunity.
  27. (2007). Viral suppression of the interferon system.